Table 1.
Clinical characteristics
| Variable | Patient number | p value | ||
|---|---|---|---|---|
| Total (n = 80) | Cluster 1 (n = 53) | Cluster 2 (n = 27) | ||
| Age at diagnosis | ||||
| < 60 | 35 | 18 | 16 | 0.058 |
| ≥ 60 | 45 | 35 | 11 | |
| Sex | ||||
| Male | 58 | 41 | 17 | 0.201 |
| Female | 22 | 12 | 10 | |
| Extent of resection (of enhancing tumor) | ||||
| Complete resection | 56 | 35 | 21 | 0.267 |
| Partial resection | 22 | 17 | 5 | |
| Biopsy | 2 | 1 | 1 | |
| MGMT-methylation status* | ||||
| Methylated | 37 | 24 | 13 | 0.929 |
| Unmethylated | 41 | 27 | 14 | |
| IDH-1 mutation status | ||||
| Mutant | 7 | 4 | 3 | 0.622 |
| Wild-type | 73 | 49 | 24 | |
| Preoperative tumor volumes (cm3) # | ||||
| Contrast-enhancing | 49.7 ± 28.1 | 50.2 ± 28.4 | 50.4 ± 28.1 | 0.823 |
| Non-enhancing | 64.7 ± 48.3 | 48.7 ± 27.9 | 92.8 ± 53.5 | 0.007 |
| Survival (days) | ||||
| Median OS (range) | 461 (52–1259) | 424 (52–839) | 689 (109–1259) | 0.020 † |
| Median PFS (range) | 264(25–1130) | 248 (25–607) | 318 (279–1130) | < 0.001 † |
Italics: p < 0.05
*MGMT-methylation status unavailable for 2 patients; #mean ± SD of original data; †log-rank test
MGMT O-6-methylguanine-DNA methyltransferase, IDH-1 isocitrate dehydrogenase 1, OS overall survival, PFS progression-free survival